China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
One Percent Rule Checklist For Safer Forex Trading Risk 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
TEL AVIV, Israel, April 06, 2017 -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today the cancellation of its previously announced underwritten public offering of the company’s securities due to adverse market conditions. The offering was conducted pursuant to a registration statement Form F-1 filed with the U.S. Securities and Exchange Commission.
The Company will provide a business update in the near future that deals with its financing plans and clinical development program for patients with Ocular Pharyngeal Muscular Dystrophy (OPMD) using its investigational proprietary intravenous (IV) form of trehalose 90 mg/mL solution.
About Bioblast Pharma Ltd.
Bioblast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Bioblast is traded on the NASDAQ under the symbol “ORPN”. For more information, please visit our website: www.BioblastPharma.com, the content of which is not incorporated herein by reference.
INVESTOR CONTACT Matthew P. Duffy Managing Director LifeSci Advisors LLC [email protected] Phone: 212-915-0685
